Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Determinants of selective reporting: A taxonomy based on content analysis of a random selection of the literature.

van der Steen JT, van den Bogert CA, van Soest-Poortvliet MC, Fazeli Farsani S, Otten RHJ, Ter Riet G, Bouter LM.

PLoS One. 2018 Feb 5;13(2):e0188247. doi: 10.1371/journal.pone.0188247. eCollection 2018.

2.

Pharmacological vs. classical approaches in the design of first in man clinical drug trials.

van den Bogert CA, Cohen AF, Leufkens HGM, van Gerven JMA.

Br J Clin Pharmacol. 2017 Dec;83(12):2807-2812. doi: 10.1111/bcp.13422. Epub 2017 Oct 6.

PMID:
28975652
3.

[Non-publication is common among phase 1, single-center, not prospectively registered, or early terminated clinical drug trials].

van den Bogert CA, Souverein PC, Brekelmans CTM, Janssen SWJ, Koëter GH, Leufkens HGM, Bouter LM.

Ned Tijdschr Geneeskd. 2017;161:D1498. Dutch.

PMID:
28659210
4.

Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study.

van den Bogert CA, Souverein PC, Brekelmans CTM, Janssen SWJ, Koëter GH, Leufkens HGM, Bouter LM.

J Clin Epidemiol. 2017 Sep;89:199-208. doi: 10.1016/j.jclinepi.2017.05.012. Epub 2017 May 20.

PMID:
28535887
5.

Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands.

van den Bogert CA, Souverein PC, Brekelmans CTM, Janssen SWJ, Koëter GH, Leufkens HGM, Bouter LM.

J Clin Epidemiol. 2017 Aug;88:140-147. doi: 10.1016/j.jclinepi.2017.05.001. Epub 2017 May 6.

PMID:
28487159
6.

Generic drugs have lost their profitability.

van den Bogert CA.

BMJ. 2017 Mar 27;356:j1526. doi: 10.1136/bmj.j1526. No abstract available.

PMID:
28347996
7.

Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.

van den Bogert CA, Souverein PC, Brekelmans CT, Janssen SW, Koëter GH, Leufkens HG, Bouter LM.

PLoS One. 2016 Dec 14;11(12):e0167709. doi: 10.1371/journal.pone.0167709. eCollection 2016.

8.

Risk indicator taxonomy for supervision of clinical trials on medicinal products.

Jongen PM, van den Bogert CA, van de Laar CW, Notenboom K, Hille ET, Hegger I.

Curr Med Res Opin. 2016 Jul;32(7):1269-76. doi: 10.1185/03007995.2016.1170671. Epub 2016 Apr 21.

PMID:
27009363
9.

Need for a proactive and structured approach to risk analysis when designing phase I trials.

Van den Bogert CA, Cohen AF.

BMJ. 2015 Jul 22;351:h3899. doi: 10.1136/bmj.h3899. No abstract available.

PMID:
26201349
10.

Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study.

van den Bogert CA, Souverein PC, Brekelmans CT, Janssen SW, van Hunnik M, Koëter GH, Leufkens HG, Bouter LM.

BMJ Open. 2015 Jul 7;5(7):e007827. doi: 10.1136/bmjopen-2015-007827.

11.

Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?

van den Bogert CA, Souverein PC, Putzeist M, Leufkens HG, Janssen SW, Koëter GH.

Nat Rev Drug Discov. 2014 Dec;13(12):878. doi: 10.1038/nrd4468. Epub 2014 Nov 14. No abstract available.

PMID:
25394870
12.

Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk Knowledge.

van den Bogert CA, Miller MJ, Cobaugh DJ, Chen L, Allison JJ, Saag KG.

J Patient Saf. 2017 Dec;13(4):217-222. doi: 10.1097/PTS.0000000000000143.

PMID:
25275383
13.

Assembly of cytochrome-c oxidase in cultured human cells.

Nijtmans LG, Taanman JW, Muijsers AO, Speijer D, Van den Bogert C.

Eur J Biochem. 1998 Jun 1;254(2):389-94.

14.

Familial mitochondrial DNA depletion in liver: haplotype analysis of candidate genes.

Spelbrink JN, Van Galen MJ, Zwart R, Bakker HD, Rovio A, Jacobs HT, Van den Bogert C.

Hum Genet. 1998 Mar;102(3):327-31.

PMID:
9544847
15.

Preferential amplification and phenotypic selection in a population of deleted and wild-type mitochondrial DNA in cultured cells.

Spelbrink JN, Zwart R, Van Galen MJ, Van den Bogert C.

Curr Genet. 1997 Aug;32(2):115-24.

PMID:
9294259
16.

Cerebellar hypoplasia in respiratory chain dysfunction.

Lincke CR, van den Bogert C, Nijtmans LG, Wanders RJ, Tamminga P, Barth PG.

Neuropediatrics. 1996 Aug;27(4):216-8.

PMID:
8892374
17.

Depletion of mitochondrial deoxyribonucleic acid in a family with fatal neonatal liver disease.

Bakker HD, Scholte HR, Dingemans KP, Spelbrink JN, Wijburg FA, Van den Bogert C.

J Pediatr. 1996 May;128(5 Pt 1):683-7.

PMID:
8627442
18.

Depletion of mitochondrial DNA in the liver of a patient with lactic acidemia and hypoketotic hypoglycemia.

Maaswinkel-Mooij PD, Van den Bogert C, Scholte HR, Onkenhout W, Brederoo P, Poorthuis BJ.

J Pediatr. 1996 May;128(5 Pt 1):679-83.

PMID:
8627441
19.

X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory-chain abnormalities in cultured fibroblasts.

Barth PG, Van den Bogert C, Bolhuis PA, Scholte HR, van Gennip AH, Schutgens RB, Ketel AG.

J Inherit Metab Dis. 1996;19(2):157-60. No abstract available.

PMID:
8739954
20.

Progressive generalized brain atrophy and infantile spasms associated with cytochrome c oxidase deficiency.

Bakker HD, Van den Bogert C, Drewes JG, Barth PG, Scholte HR, Wanders RJ, Ruitenbeek W.

J Inherit Metab Dis. 1996;19(2):153-6. No abstract available.

PMID:
8739953
21.

Fatal neonatal liver failure and depletion of mitochondrial DNA in three children of one family.

Bakker HD, Van den Bogert C, Scholte HR, Zwart R, Wijburg FA, Spelbrink JN.

J Inherit Metab Dis. 1996;19(2):112-4. No abstract available.

PMID:
8739942
22.

Assembly of mitochondrial ATP synthase in cultured human cells: implications for mitochondrial diseases.

Nijtmans LG, Klement P, Houstĕk J, van den Bogert C.

Biochim Biophys Acta. 1995 Dec 12;1272(3):190-8.

23.

The mitochondrial DNA mutation ND6*14,484C associated with leber hereditary optic neuropathy, leads to deficiency of complex I of the respiratory chain.

Oostra RJ, Van Galen MJ, Bolhuis PA, Bleeker-Wagemakers EM, Van den Bogert C.

Biochem Biophys Res Commun. 1995 Oct 24;215(3):1001-5.

PMID:
7488023
24.
25.

Simultaneous occurrence of the 11778 (ND4) and the 9438 (COX III) mtDNA mutations in Leber hereditary optic neuropathy: molecular, biochemical, and clinical findings.

Oostra RJ, Van den Bogert C, Nijtmans LG, van Galen MJ, Zwart R, Bolhuis PA, Bleeker-Wagemakers EM.

Am J Hum Genet. 1995 Oct;57(4):954-7. No abstract available.

27.

[Diseases caused by mitochondrial DNA mutations].

Wijburg FA, van den Bogert C, de Visser M, Oostra RJ, Bakker PA, Bolhuis PA.

Ned Tijdschr Geneeskd. 1995 Jul 1;139(26):1322-6. Review. Dutch. No abstract available.

PMID:
7617049
28.

Altered properties of mitochondrial ATP-synthase in patients with a T-->G mutation in the ATPase 6 (subunit a) gene at position 8993 of mtDNA.

Houstĕk J, Klement P, Hermanská J, Houstková H, Hansíková H, Van den Bogert C, Zeman J.

Biochim Biophys Acta. 1995 Jun 9;1271(2-3):349-57.

29.

Altered kinetics of cytochrome c oxidase in a patient with severe mitochondrial encephalomyopathy.

Nijtmans LG, Barth PG, Lincke CR, Van Galen MJ, Zwart R, Klement P, Bolhuis PA, Ruitenbeek W, Wanders RJ, Van den Bogert C.

Biochim Biophys Acta. 1995 Apr 24;1270(2-3):193-201.

30.

Expression and fate of the nuclearly encoded subunits of cytochrome-c oxidase in cultured human cells depleted of mitochondrial gene products.

Nijtmans LG, Spelbrink JN, Van Galen MJ, Zwaan M, Klement P, Van den Bogert C.

Biochim Biophys Acta. 1995 Mar 16;1265(2-3):117-26.

31.

Meta-iodobenzylguanidine inhibits complex I and III of the respiratory chain in the human cell line Molt-4.

Cornelissen J, Wanders RJ, Van Gennip AH, Van den Bogert C, Voûte PA, Van Kuilenburg AB.

Biochem Pharmacol. 1995 Feb 14;49(4):471-7.

PMID:
7872952
32.

Meta-iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c).

Cornelissen J, Wanders RJ, Van den Bogert C, Van Kuilenburg AB, Elzinga L, Voûte PA, Van Gennip AH.

Eur J Cancer. 1995;31A(4):582-6.

PMID:
7576973
33.

The relationship between mitochondrial genotype and mitochondrial phenotype in lymphoblasts with a heteroplasmic mtDNA deletion.

Spelbrink JN, Van Oost BA, Van den Bogert C.

Hum Mol Genet. 1994 Nov;3(11):1989-97.

PMID:
7874116
34.

Combined quantitative immuno- and enzyme cytochemistry of cytochrome c oxidase in sections of neural tissue and cultured cells.

van Raamsdonk W, van den Bogert C, Smit-Onel MJ, Muijsers AO, Diegenbach PC.

Acta Histochem. 1994 Mar;96(1):19-32.

PMID:
8030381
35.

Beta-oxidation of fatty acids in cultured human skin fibroblasts devoid of the capacity for oxidative phosphorylation.

Jakobs BS, van den Bogert C, Dacremont G, Wanders RJ.

Biochim Biophys Acta. 1994 Feb 10;1211(1):37-43.

PMID:
8123680
36.

Cultured human muscle cells and respiratory chain deficiencies.

Herzberg NH, Bolhuis PA, van den Bogert C, Barth PG.

Neuromuscul Disord. 1994 Jan;4(1):3-11. Review.

PMID:
8173349
37.

Signals on proteins, intracellular targeting and inborn errors of organellar metabolism.

Tager JM, Aerts JM, van den Bogert C, Wanders RJ.

J Inherit Metab Dis. 1994;17(4):459-69. Review.

PMID:
7967496
39.

Regulation of the expression of mitochondrial proteins: relationship between mtDNA copy number and cytochrome-c oxidase activity in human cells and tissues.

Van den Bogert C, De Vries H, Holtrop M, Muus P, Dekker HL, Van Galen MJ, Bolhuis PA, Taanman JW.

Biochim Biophys Acta. 1993 Sep 13;1144(2):177-83.

PMID:
8396443
40.

Mitochondria in cultured human muscle cells depleted of mitochondrial DNA.

Herzberg NH, Middelkoop E, Adorf M, Dekker HL, Van Galen MJ, Van den Berg M, Bolhuis PA, Van den Bogert C.

Eur J Cell Biol. 1993 Aug;61(2):400-8.

PMID:
8223726
41.

Deficiency of the adenine nucleotide translocator in muscle of a patient with myopathy and lactic acidosis: a new mitochondrial defect.

Bakker HD, Scholte HR, Van den Bogert C, Ruitenbeek W, Jeneson JA, Wanders RJ, Abeling NG, Dorland B, Sengers RC, Van Gennip AH.

Pediatr Res. 1993 Apr;33(4 Pt 1):412-7.

PMID:
8479824
42.

Differentiation and proliferation of respiration-deficient human myoblasts.

Herzberg NH, Zwart R, Wolterman RA, Ruiter JP, Wanders RJ, Bolhuis PA, van den Bogert C.

Biochim Biophys Acta. 1993 Mar 24;1181(1):63-7.

PMID:
7681329
43.

Adenine nucleotide translocator deficiency in muscle: potential therapeutic value of vitamin E.

Bakker HD, Scholte HR, Van den Bogert C, Jeneson JA, Ruitenbeek W, Wanders RJ, Abeling NG, van Gennip AH.

J Inherit Metab Dis. 1993;16(3):548-52. No abstract available.

PMID:
7609449
44.

Relationship between culture conditions and the dependency on mitochondrial function of mammalian cell proliferation.

van den Bogert C, Spelbrink JN, Dekker HL.

J Cell Physiol. 1992 Sep;152(3):632-8.

PMID:
1506419
45.

Steady-state transcript levels of cytochrome c oxidase genes during human myogenesis indicate subunit switching of subunit VIa and co-expression of subunit VIIa isoforms.

Taanman JW, Herzberg NH, De Vries H, Bolhuis PA, Van den Bogert C.

Biochim Biophys Acta. 1992 Jun 9;1139(1-2):155-62.

PMID:
1319212
46.

Subunit IV of human cytochrome c oxidase, polymorphism and a putative isoform.

Van Kuilenburg AB, Van Beeumen JJ, Demol H, Van den Bogert C, Schouten I, Muijsers AO.

Biochim Biophys Acta. 1992 Feb 26;1119(2):218-24.

PMID:
1311608
47.

Isoforms of cytochrome c oxidase in tissues and cell lines of the mouse.

Van den Bogert C, Dekker HL, Cornelissen JC, Van Kuilenburg AB, Bolhuis PA, Muijsers AO.

Biochim Biophys Acta. 1992 Feb 21;1099(2):118-22.

PMID:
1311949
48.

Quantification of mitochondrial proteins in cultured cells by immuno-flow cytometry.

Van den Bogert C, Pennings A, Dekker HL, Luciaková K, Boezeman JB, Sinjorgo KM.

Biochim Biophys Acta. 1991 Sep 23;1097(2):87-94.

PMID:
1655047
49.

Isoforms of human cytochrome-c oxidase. Subunit composition and steady-state kinetic properties.

Van Kuilenburg AB, Dekker HL, Van den Bogert C, Nieboer P, Van Gelder BF, Muijsers AO.

Eur J Biochem. 1991 Aug 1;199(3):615-22.

50.

1-beta-D-arabinofuranosylcytosine (Ara-C) enhances mitochondrial activities in human leukaemic cells.

Muus P, Van den Bogert C, De Vries H, Pennings A, Holtrop M, Haanen C.

Br J Cancer. 1991 Jul;64(1):29-34.

Supplemental Content

Loading ...
Support Center